| 701 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
France |
65 |
| 702 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
hematology |
2026 |
Standard Therapy |
Germany |
75 |
| 703 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
Germany |
57 |
| 704 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
Germany |
72 |
| 705 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
Germany |
32 |
| 706 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
Bulgaria |
63 |
| 707 |
Apheresis |
Allogeneic |
Myelofibrosis |
hematology |
2026 |
Standard Therapy |
Hungary |
52 |
| 708 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
hematology |
2026 |
Standard Therapy |
Germany |
64 |
| 709 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
hematology |
2026 |
Standard Therapy |
Poland |
24 |
| 710 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
Germany |
59 |
| 711 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
hematology |
2026 |
Standard Therapy |
Belgium |
65 |
| 712 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
hematology |
2026 |
Standard Therapy |
USA |
65 |
| 713 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
hematology |
2026 |
Standard Therapy |
USA |
47 |
| 714 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
hematology |
2026 |
Standard Therapy |
Sweden |
21 |
| 715 |
Apheresis |
Autologous |
Multiple Myeloma |
hematology |
2026 |
Standard Therapy |
Portugal |
57 |
| 716 |
Apheresis |
Autologous |
Multiple Myeloma |
hematology |
2026 |
Standard Therapy |
Portugal |
68 |
| 717 |
Apheresis |
Allogeneic |
Chronic Lymphocytic Leukemia |
Hematology |
2026 |
Standard therapy |
Germany |
69 |
| 718 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard therapy |
Germany |
59 |
| 719 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2026 |
Standard therapy |
Germany |
40 |
| 720 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard therapy |
Germany |
61 |
| 721 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard therapy |
Germany |
46 |
| 722 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2026 |
Standard therapy |
Germany |
66 |
| 723 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard therapy |
Germany |
64 |
| 724 |
Apheresis |
Allogeneic |
Myeloid Sarcoma |
Hematology |
2026 |
Standard therapy |
Germany |
57 |
| 725 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2026 |
Standard therapy |
Germany |
38 |
| 726 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard therapy |
Germany |
69 |
| 727 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Germany |
52 |
| 728 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2026 |
Standard therapy |
USA |
22 |
| 729 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
70 |
| 730 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Argentina |
35 |
| 731 |
Apheresis |
Allogeneic |
Adenosine Deaminase 2 (ADA2) Deficiency |
Hematology |
2026 |
Standard therapy |
Germany |
23 |
| 732 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
41 |
| 733 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard therapy |
Poland |
67 |
| 734 |
Apheresis |
Allogeneic |
Anaplastic Lymphoma |
Hematology |
2026 |
Standard therapy |
Portugal |
58 |
| 735 |
Apheresis |
Allogeneic |
Thalassemia Major |
Hematology |
2026 |
Standard therapy |
India |
3 |
| 736 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2026 |
Standard therapy |
Poland |
58 |
| 737 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
France |
22 |
| 738 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Germany |
50 |
| 739 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2026 |
Standard therapy |
Canada |
61 |
| 740 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
Poland |
9 |
| 741 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2026 |
Standard therapy |
Germany |
48 |
| 742 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Poland |
56 |
| 743 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
67 |
| 744 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
United Kingdom |
46 |
| 745 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Russian Federation |
28 |
| 746 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2026 |
Standard therapy |
Germany |
51 |
| 747 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Australia |
67 |
| 748 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard therapy |
USA |
51 |
| 749 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
34 |
| 750 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Lithuania |
37 |
| 751 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Canada |
72 |
| 752 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2026 |
Standard therapy |
Germany |
61 |
| 753 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard therapy |
Germany |
65 |
| 754 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard therapy |
United Kingdom |
19 |
| 755 |
Apheresis |
Allogeneic |
T-cell Prolymphocytic Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
46 |
| 756 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Canada |
70 |
| 757 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
Chile |
9 |
| 758 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard therapy |
Belarus |
17 |
| 759 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
61 |
| 760 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2026 |
Standard therapy |
Poland |
61 |
| 761 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2026 |
Standard therapy |
Spain |
59 |
| 762 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard therapy |
Germany |
64 |
| 763 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
USA |
39 |
| 764 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard therapy |
Poland |
64 |
| 765 |
Cord Tissue |
Allogeneic – Related |
Chronic renal disease |
Endocrinology |
2025 |
Experimental Therapy |
Romania |
50 |
| 766 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2025 |
Experimental Therapy |
Romania |
6 |
| 767 |
Cord Tissue |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Romania |
6 |
| 768 |
Cord Tissue |
Allogeneic – Unrelated |
Degenerative and traumatic cartilage damage |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
57,2 |
| 769 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
3,1 |
| 770 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
3,4 |
| 771 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
2,8 |
| 772 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,9 |
| 773 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
11,9 |
| 774 |
Cord Tissue |
Allogeneic – Unrelated |
Degenerative and traumatic cartilage damage |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
54,2 |
| 775 |
Cord Tissue |
Allogeneic – Unrelated |
Degenerative and traumatic cartilage damage |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
78,4 |
| 776 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
6,8 |
| 777 |
Cord Tissue |
Allogeneic – Unrelated |
Degenerative and traumatic cartilage damage |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
58,2 |
| 778 |
Cord Tissue |
Autologous |
Autism |
Neurology |
2025 |
Experimental Therapy |
Romania |
5 |
| 779 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2025 |
Experimental Therapy |
Romania |
5 |
| 780 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
4,1 |
| 781 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,9 |
| 782 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,8 |
| 783 |
Cord Tissue |
Allogeneic – Unrelated |
Degenerative and traumatic cartilage damage |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
25,8 |
| 784 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
6,8 |
| 785 |
Cord Tissue |
Allogeneic – Unrelated |
Progressive bulbar palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
62,3 |
| 786 |
Cord Tissue |
Allogeneic – Unrelated |
Encephalopathy |
Neurology |
2025 |
Experimental Therapy |
Poland |
67,2 |
| 787 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,8 |
| 788 |
Cord Tissue |
Allogeneic – Unrelated |
Degenerative and traumatic cartilage damage |
Orthopedics |
2025 |
Experimental Therapy |
Poland |
61,9 |
| 789 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,11 |
| 790 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
6,8 |
| 791 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
1,5 |
| 792 |
Cord Tissue |
Allogeneic – Unrelated |
Myelitis |
Neurology |
2025 |
Experimental Therapy |
Poland |
38,8 |
| 793 |
Cord Tissue |
Allogeneic – Unrelated |
Anemia |
Neurology |
2025 |
Experimental Therapy |
Poland |
3,2 |
| 794 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
6,8 |
| 795 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
7,1 |
| 796 |
Cord Tissue |
Allogeneic – Unrelated |
Spinocerebellar Ataxia |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,1 |
| 797 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
1,2 |
| 798 |
Cord Tissue |
Allogeneic – Unrelated |
Cerebral Palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
1,1 |
| 799 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2025 |
Experimental Therapy |
Poland |
5,11 |
| 800 |
Cord Tissue |
Allogeneic – Unrelated |
Progressive bulbar palsy |
Neurology |
2025 |
Experimental Therapy |
Poland |
63 |